Transarterial Infusion of Cisplatin and Doxorubicin in Bladder Cancer: Original Article

References

• Skinner D G. Current perspectives in the management of high grade invasive bladder cancer. Cancer 1980; 45: 1866–74
   Web of Science ®Google Scholar
• Whitemore W F. Integrated irradiation and cystectomy for bladder cancer. Br J Urol 1980; 52: 1–9
   PubMedGoogle Scholar
• Raghvan D. Pre-emptive (neo-adjuvant) intravenous chemotherapy for invasive bladder cancer. Br J Urol 1988; 61: 1–8
   PubMedGoogle Scholar
• Scher H I, Herr H, Sternberg C, et al. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with M-VAC regimen. Br J Urol 1989; 64: 250–6
   PubMedGoogle Scholar
• Logothetics C J, Samuels M L, Ogden S. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol 1985; 134: 460–4
   PubMed Web of Science ®Google Scholar
• Logothetics C J, Samuels M L, Selig D E, Wallace S, Johnson D E. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin and cisplatin (CISCA) in the management of selected patients with invasive urothelial tumors. Cancer Treat Rep 1985; 69: 33–7
   PubMedGoogle Scholar
• Japanese Urological Association. The report of clinical statistical studies on registered bladder cancer patient in Japan 1993; 14
   Google Scholar
• Hodson N J, Husband J E, MacDonald J S. The role of computed tomography in the staging of bladder cancer. Clin Radiol 1979; 30: 389–95
   PubMed Web of Science ®Google Scholar
• Prout G R, Jr. Bladder carcinoma and a TNM system of classification. J Urol 1977; 117: 583–8
   PubMed Web of Science ®Google Scholar
• WHO Handbook for reporting results of cancer treatment. WHO Offset Publication, Geneva 1979; 48: 27
   Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457–63
   Web of Science ®Google Scholar
• Chen H S, Gross J F. Intra-arterial infusion of anticancer drugs. Cancer Treat Rep 1980; 64: 31–5
   PubMedGoogle Scholar
• Collins J M. Pharmacokinetic rationale for intraarterial therapy. Intra-arterial and intracavitary cancer chemotherapy, S B Howell. Martinus Nijhoff, Boston 1984; 1–10
   Google Scholar
• Wallace S, Chuang V P, Samuels M, Johnson D. Tran-scatheter intraarterial infusion of chemotherapy in advanced bladder cancer. Cancer 1982; 49: 640–5
   PubMed Web of Science ®Google Scholar
• Stewart D J, Futter N, Maroun J A, Murphy P, McKay D, Rasuli P. Intra-arterial cisplatin treatment of unresectable or medically inoperable invasive carcinoma of the Bladder. J Urol 1984; 131: 258–26
   PubMed Web of Science ®Google Scholar
• Galetti T P, Pontes J E, Motie J, Medendorp S V, Bukowski R. Neoadjuvant Intra-arterial chemotherapy in the treatment of advanced Transitional cell carcinoma of the Bladder: Results and follow-up. J Urol 1989; 142: 1211–5
   PubMed Web of Science ®Google Scholar
• Jacobs S C, Menashe D S, Mewissen M W, Lipchik E O. Intraarterial cisplatin infusion in the management of transitional cell carcinoma of the bladder. Cancer 1989; 64: 388–391
   PubMed Web of Science ®Google Scholar
• Nicolaos E M, John T H. Platinum nephrotoxicity.
   Google Scholar
• Rozan R, Albuisson E, Donnarieix D, et al. Interstitial iridium-192 for bladder cancer (a multicentric survey: 205 patients). Int J Radiation Oncology Biol Phys 1992; 24: 469–77
   PubMed Web of Science ®Google Scholar
• Slack N H, Prout G R, Jr. The heterogeneity of invasive bladder carcinoma and different response to treatment. J Urol 1980; 123: 644–52
   PubMed Web of Science ®Google Scholar
• Shipley W U, Coombs L J, Einstein A B, Jr., Soloway M S, Wajsman Z, Prout G R, Jr., National bladder cancer collaborative group A. Cisplatin and full dose irradiation for patients with invasive bladder carcinoma. A preliminary report of tolerance and local response. J Urol 1984; 132: 899–903
   PubMed Web of Science ®Google Scholar
• Marshall V F. Current clinical problems regarding bladder tumors. Cancer 1956; 9: 543
   PubMed Web of Science ®Google Scholar
• Goldie J, Coldman A J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–33
   PubMedGoogle Scholar
• Scher H I, Yagoda A, Herr H W, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 1988; 139: 470–4
   PubMed Web of Science ®Google Scholar
• Sternberg C N, Yagoda A, Scher H I, et al. M-VAC (methotrexate, vinblastin, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461–9
   PubMed Web of Science ®Google Scholar
• Logothetis C J, Dexeus F H, Chong C, Sella A, Ayala A G, Pilat S. Cisplatin, cylophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors. The M.D. Anderson Hospital experience. J Urol 1989; 141: 33–7
   PubMed Web of Science ®Google Scholar
• Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastin, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 1989; 142: 289–92
   PubMed Web of Science ®Google Scholar
• Stewart D J, Benjamin R S, Zimmerman S, et al. Clinical pharmacology of intraarterial cisdiamine dichloroplatinum (II). Cancer Res 1983; 43: 917
   PubMed Web of Science ®Google Scholar